Kymera Therapeutics KYMR Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$311.35M-39.1% | -$223.86M-52.3% | -$146.96M+5.1% | -$154.81M-54.5% | ||
| $8.31M+12.7% | $7.37M+107% | $3.57M+19.8% | $2.98M+24.2% | ||
| $59.9M+8.9% | $55.01M+27.6% | $43.12M+21.5% | $35.48M+42.1% | ||
| -$232.89M-19.7% | -$194.5M-75.4% | -$110.87M+27.6% | -$153.09M-18.7% | ||
| $1.45M-88.9% | $13.03M-62.2% | $34.48M+1,116% | $2.84M+77.6% | ||
| -$521.06M— | —— | $139.89M— | —— | ||
| $990.71M+62.7% | $608.85M+13,744% | $4.4M-97.1% | $153M-38.9% | ||
| $236.76M+2,205% | $10.27M-75.1% | $41.25M— | —— | ||
| -$234.34M-13.0% | -$207.34M-51.0% | -$137.31M+11.9% | -$155.92M-19.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Kymera Therapeutics generate?
- Kymera Therapeutics (KYMR) generated -$242.6M in operating cash flow over the trailing twelve months.
- What is Kymera Therapeutics's free cash flow?
- After $1.4M of capital expenditures, Kymera Therapeutics's free cash flow was -$244.0M over the trailing twelve months, down 1.7% year over year.
- Where does Kymera Therapeutics's cash flow data come from?
- Every line is extracted from Kymera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
